Investigational drug · Phase 3
Ifupinostat Hydrochloride
Also called: BEBT-908, CUDC-908
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Previously Untreated Peripheral T-Cell Lymphoma, Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "Ifupinostat Hydrochloride"
First trial start
2025
Jan 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ifupinostat Hydrochloride", any sponsor or status.
Conditions studied
As listed on its trial records.
- Previously Untreated Peripheral T-Cell Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Ifupinostat Hydrochloride" as an intervention, largest first.
- Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaPivotal-lookingRecruiting
BeBetter Med IncIndustry
NCT06792253 · 416 participants (planned) · Start Jan 6, 2025 · Primary completion Dec 31, 2028
Drug: Ifupinostat Hydrochloride for Injection; Rituximab Injection and 5 more · For: Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Sites: Beijing, China
- A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)Pivotal-lookingNot yet recruiting
BeBetter Med IncIndustry
NCT07676175 · 120 participants (planned) · Start Jul 1, 2026 · Primary completion Jan 31, 2028
Drug: Ifupinostat Hydrochloride for Injection; Cyclophosphamide for Injection and 3 more · For: Previously Untreated Peripheral T-Cell Lymphoma
Sites: Guangzhou, China; Xi’an, China; Tianjin, China
The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
NCT07854652 · 15 participants (planned) · Start Dec 1, 2026 · Primary completion Aug 30, 2028
Drug: Ifupinostat Hydrochloride · For: B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Sites: Suzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of ifupinostat in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase 2 study.
Shi Y, Liu P, Li Y, et al. · Signal Transduct Target Ther 2026
- Targeting PI3Kα with Small Molecules: Progress and Challenges in Tumor Treatment.
Jia W · Curr Issues Mol Biol 2026
- Dual HDAC/PI3K inhibitors as a potential and emerging cancer therapy: a review.
Madhukumari, Handattu Shankaranarayana A, P Nair S, et al. · Future Med Chem 2026
- Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma.
Wang N, Mo Z, Pan L, et al. · Target Oncol 2023
- A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy.
Fan F, Liu P, Bao R, et al. · Cancer Res 2021
- Retraction notice to "BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma" [Biochem. Biophys. Res. Commun. 491 (2017) 939-945].
Li J, Qian C, Zhou Q, et al. · Biochem Biophys Res Commun 2018
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.